Multiple sclerosis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD20 17
• CD19 9
• PPAR 0
• NLRP3 0
• STAT3 0
• BCMA 13
• NRF2 0
• TNF 0
• AQP4 0
• IL-17 0
• BTK 1
• GLP-1 2
• AMPK 0
• BDNF 1
• AKT 0
• IL-6 0
• mTOR 0
• CD40 0
• JAK 0
• PI3K 0
• STING 0
• TREM2 0
• PD-1 0
• IL-1 0
• IL-4 0
• SIRT1 0
• TLR4 0
• AXL 0
• CGRP 0
• CSF1R 0
• HIF-1 0
• IL-23 0
• VEGF 1
• COX-2 0
• CTLA-4 0
• CXCR4 0
• ERK 0
• HMGB1 0
• HSP90 0
• PD-L1 0
• TYK2 1
• APOE 0
• CCR5 0
• CTNNB1 0
• EGFR 0
• FOXP3 0
• GPX4 0
• IDO1 0
• JNK 0
• PARP 0
• PTEN 0
• TP53 1
• ACE2 0
• APP 0
• BCL-2 0
• BRD4 0
• C9orf72 0
• CDK4/6 0
• G6PD 0
• HDAC 0

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

  NCT07361094· Beijing Boren Hospital· Updated 15 Oct 2026

  “No participants.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 16
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 3
• Gene Expression Profiling 38
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 34
• Metabolomics 21
• Mass Spectrometry 12
• Flow Cytometry 29
• Immunohistochemistry 10
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 28
• Magnetic Resonance Imaging 563
• Machine Learning 43
• Deep Learning 32
• Cohort Studies 182
• Genome-Wide Association Study 84

• Rapid whole-brain susceptibility source separation using sub-minute three-dimensional multiple overlapping-echo detachment acquisition.

  Phys Med Biol, Sept 2026

• RobustT1ρ,T2, andT2*mapping via spin-locked MOLED with synthetic data-driven deep learning reconstruction.

  Phys Med Biol, Aug 2026

• A Generalized Approach to Solving Deep Learning-Based Quantitative Susceptibility Mapping and Quantitative Blood Oxygen Level Dependent Magnitude (QSM + qBOLD or QQ) for Oxygen Extraction Fraction (OEF) Mapping Across Diverse Acquisition Schemes.

  Magn Reson Med, Aug 2026

• MIF-MAPMS: Enhancing identification of myelin autoantigenic peptides in multiple sclerosis through multimodal information fusion.

  Protein Sci, Aug 2026

• Fast Submillimeter Whole-Brain T2*-Weighted Imaging Using 3D-EPI With CAIPIRINHA and Deep-Learning Denoising at 3T.

  Magn Reson Med, Jul 2026

• Deep Learning-Based Automated Detection and Burden Assessment of Paramagnetic Rim Lesions on Quantitative Susceptibility Mapping in Patients With Multiple Sclerosis.

  Korean J Radiol, Jun 2026

• Whole anterior visual pathway segmentation from high-resolution MRI using artificial intelligence.

  Eur Radiol Exp, Jun 2026

• Deep Learning-Accelerated 3D FLAIR Enables Reliable MS Lesion Detection.

  AJNR Am J Neuroradiol, Jun 2026

• Deep learning-based neuroanatomical profiling reveals population-specific brain changes in multiple sclerosis: a large-scale Middle Eastern study.

  BMC Med Imaging, Jun 2026

• A Z-Score Template Method for Person-Specific Augmentation of Clinical Brain MRI: An Investigation in Multiple Sclerosis.

  NMR Biomed, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.